Related Experiment Video

Updated: May 14, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Neurodevelopment after moderate hyperbilirubinemia at term

Roelineke J Lunsing1, Willem F H Pardoen, Mijna Hadders-Algra

  • 1Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. r.j.lunsing@umcg.nl

Pediatric Research
|February 15, 2013
PubMed

Insights

Moderate hyperbilirubinemia in newborns did not increase minor neurological dysfunction (MND). However, higher bilirubin levels (≥ 300 µmol/l) were linked to increased risk of complex MND and subtle behavioral issues in infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Neurology
  • Developmental Pediatrics

Background:

  • Investigating the long-term effects of moderate hyperbilirubinemia in healthy term neonates.
  • Assessing potential links between elevated bilirubin levels and neurological or behavioral outcomes.
  • Understanding the clinical significance of jaundice in newborn infants.

Purpose of the Study:

  • To prospectively examine if moderate hyperbilirubinemia in healthy term neonates is associated with increased minor neurological dysfunction (MND) and behavioral problems up to 18 months of age.
  • To determine the threshold of bilirubin levels that may pose a risk for neurological and behavioral development.
  • To evaluate the incidence of MND and behavioral changes in infants with and without hyperbilirubinemia.

Main Methods:

  • Prospective study enrolling 43 healthy term infants with bilirubin levels ≥ 220 µmol/l (BILI group) and 70 controls (COMP group).
  • Neurologic condition assessed neonatally and at 3 and 18 months; behavior evaluated at birth and 18 months.
  • Statistical analysis included odds ratios and confidence intervals to compare outcomes between groups.

Main Results:

  • No significant difference in overall MND rates between BILI and COMP groups at any age.
  • Bilirubin levels ≥ 300 µmol/l were associated with an increased risk of complex MND (OR: 4.21).
  • BILI infants showed increased lethargy neonatally (OR: 3.54) and higher hyperactivity scores at 18 months (effect: 0.32).

Conclusions:

  • Moderate hyperbilirubinemia did not lead to different rates of complex MND at 18 months compared to controls.
  • Bilirubin levels ≥ 300 µmol/l correlated with an elevated risk of complex MND.
  • Minor behavioral effects, such as increased hyperactivity, associated with moderate hyperbilirubinemia cannot be ruled out.
Abstract

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the anterior...